Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Jupiter Neurosciences (JUNS) has announced the pricing of its initial public offering of 2,750,000 shares at $4.00 per share, expecting to raise $11 million in gross proceeds. Trading will commence on Nasdaq Capital Market on December 3, 2024, under the symbol 'JUNS'. The company plans to use proceeds to fund Phase II clinical trials of JOTROL™ for Parkinson's Disease, expand business in South-East Asia, conduct R&D, pay license fees to Aquanova AG, repay debt, and support working capital. The offering is led by Dominari Securities with Revere Securities as co-manager.
Jupiter Neurosciences (JUNS) ha annunciato il prezzo della sua offerta pubblica iniziale di 2.750.000 azioni a $4,00 per azione, prevedendo di raccogliere $11 milioni in proventi lordi. Le contrattazioni inizieranno sul Nasdaq Capital Market il 3 dicembre 2024, con il simbolo 'JUNS'. L'azienda prevede di utilizzare i proventi per finanziare gli studi clinici di Fase II di JOTROL™ per il Morbo di Parkinson, ampliare il business nel Sud-Est asiatico, condurre R&D, pagare le royalty a Aquanova AG, ripagare debiti e supportare il capitale circolante. L'offerta è guidata da Dominari Securities con Revere Securities come co-manager.
Jupiter Neurosciences (JUNS) ha anunciado el precio de su oferta pública inicial de 2,750,000 acciones a $4.00 por acción, esperando recaudar $11 millones en ingresos brutos. Las negociaciones comenzarán en el Nasdaq Capital Market el 3 de diciembre de 2024, bajo el símbolo 'JUNS'. La compañía planea utilizar los ingresos para financiar ensayos clínicos de Fase II de JOTROL™ para la enfermedad de Parkinson, expandir su negocio en el sudeste asiático, llevar a cabo investigación y desarrollo, pagar tarifas de licencia a Aquanova AG, reembolsar deudas y apoyar el capital de trabajo. La oferta está liderada por Dominari Securities con Revere Securities como co-administrador.
주피터 뉴로사이언스(JUNS)는 2,750,000주를 주당 $4.00에 발행하는 상장공모 가격을 발표하며, 총 $11백만의 모집금액을 기대하고 있습니다. 거래는 2024년 12월 3일부터 나스닥 자본시장에서 'JUNS' 기호로 시작될 예정입니다. 이 회사는 모금액을 사용하여 파킨슨병 치료제 JOTROL™의 2상 임상시험을 자금 지원하고, 동남아시아에서 사업을 확장하며, 연구개발을 수행하고, Aquanova AG에 라이선스 요금을 지불하고, 부채를 상환하며, 운영 자본을 지원할 계획입니다. 이번 공모는 Dominari Securities가 주관하고 Revere Securities가 공동 관리합니다.
Jupiter Neurosciences (JUNS) a annoncé le prix de son offre publique initiale de 2.750.000 actions à 4,00 $ par action, s'attendant à lever 11 millions de dollars en recettes brutes. La négociation débutera sur le Nasdaq Capital Market le 3 décembre 2024, sous le symbole 'JUNS'. La société prévoit d'utiliser les fonds pour financer les essais cliniques de Phase II de JOTROL™ pour la maladie de Parkinson, d'étendre ses activités en Asie du Sud-Est, de mener des recherches et du développement, de payer des redevances à Aquanova AG, de rembourser des dettes et de soutenir le fonds de roulement. L'offre est dirigée par Dominari Securities avec Revere Securities comme co-manager.
Jupiter Neurosciences (JUNS) hat den Preis für ihr öffentliche Angebot von 2.750.000 Aktien zu je $4,00 bekannt gegeben und erwartet, insgesamt $11 Millionen Bruttoeinnahmen zu generieren. Der Handel wird am Nasdaq Capital Market am 3. Dezember 2024 unter dem Symbol 'JUNS' beginnen. Das Unternehmen plant, die Einnahmen zur Finanzierung der Phase-II-Studien von JOTROL™ für die Parkinson-Krankheit zu nutzen, das Geschäft in Südostasien auszubauen, Forschung und Entwicklung durchzuführen, Lizenzgebühren an Aquanova AG zu zahlen, Schulden zurückzuzahlen und das Betriebskapital zu unterstützen. Das Angebot wird von Dominari Securities geleitet, mit Revere Securities als Co-Manager.
- Successful IPO raising $11 million in gross proceeds
- Nasdaq Capital Market listing enhancing visibility and access to capital
- Clear allocation of funds for Phase II clinical trials and business expansion
- Strategic expansion plans into South-East Asian markets
- Existing debt requiring repayment from IPO proceeds
- Outstanding license fees to be paid to Aquanova AG
- Potential shareholder dilution from 2,750,000 new shares
Insights
This IPO marks a significant milestone for Jupiter Neurosciences, raising
The company's plan to expand into South-East Asia through Strategic Service Agreements shows potential for market expansion, while debt repayment will strengthen the balance sheet. However, investors should note that as a clinical-stage company, success heavily depends on the outcome of their Phase II trials. The relatively modest IPO size suggests the company may need additional funding rounds depending on trial results and commercialization timeline.
JOTROL™, based on resveratrol technology, targets neuroinflammation - a key factor in neurodegenerative diseases like Parkinson's. The platform approach suggests potential applications beyond Parkinson's Disease, indicating broader market opportunities. The company's licensing agreement with Aquanova AG for the technology demonstrates established intellectual property protection, though ongoing fees represent a continued obligation.
The progression to Phase II trials is a important inflection point that will provide important efficacy data. The focus on neuroinflammation aligns with current therapeutic trends in neurodegenerative disease treatment. However, resveratrol-based therapies have historically faced bioavailability challenges, making the delivery technology critical to success.
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its unique resveratrol platform product, JOTROL™, today announced the pricing of its initial public offering (the “Offering”) of 2,750,000 shares of common stock at a price of
The shares are expected to begin trading on the Nasdaq Capital Market on December 3, 2024 under the symbol “JUNS.” The Offering is expected to close on December 4, 2024, subject to the satisfaction of customary closing conditions.
The Company expects to receive aggregate gross proceeds of
The Company intends to use the net proceeds from the Offering to fund the Phase II clinical trial of its product candidate JOTROL™ in patients with Parkinson’s Disease, Strategic Service Agreements to accelerate business activities in South-East Asia, research and development activities regarding evaluation of new product opportunities, payment of the outstanding annual license fees due to Aquanova AG, the repayment of debt, working capital and other general corporate purposes.
The Offering is conducted on a firm commitment basis. Dominari Securities LLC is acting as the lead underwriter, with Revere Securities LLC acting as the co-manager (collectively, the “Underwriters”) for the Offering.
Anthony, Linder & Cacomanolis, PLLC is acting as legal counsel to Jupiter Neurosciences and ArentFox Schiff LLP is acting as legal counsel to the Underwriters in connection with the Offering.
The Company’s Registration Statement on Form S-1 (File No. 333- 260183) relating to the securities being offered was previously filed with, and subsequently declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2024. The Offering is being made only by means of a prospectus. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus relating to the Offering may be obtained, when available, from Dominari Securities LLC by email at info@dominarisecurities.com, by standard mail to Dominari Securities LLC, 725 Fifth Avenue, 23rd Floor New York, NY 10022, or by telephone at (212) 393-4500; or from Revere Securities LLC by email at contact@reveresecurities.com, by standard mail to Revere Securities LLC, 560 Lexington Avenue, 16th Floor, New York, NY 10022, or by telephone at +1 (212) 688-2350.
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the timing of the trading of its common stock or the closing of the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contacts
Investor Relations
Alison Silva, President & CBO
a.silva@jupiterneurosciences.com
FAQ
What is the IPO price for Jupiter Neurosciences (JUNS) shares?
How many shares is Jupiter Neurosciences (JUNS) offering in its IPO?
When will JUNS stock begin trading on Nasdaq?
How will Jupiter Neurosciences use its IPO proceeds?
